Combination therapy in combating cancer.
Combination therapy in combating cancer.
复制标题
DOI：
10.18632/oncotarget.16723
复制
发表时间：
2017-06-06
期刊：
影响因子：
--
通讯作者：
Yeger H
中科院分区：
文献类型：
--
作者：
Bayat Mokhtari R;Homayouni TS;Baluch N;Morgatskaya E;Kumar S;Das B;Yeger H
联合治疗是将两种或多种治疗剂组合的治疗方式，是癌症治疗的基石。与单一治疗方法相比，抗癌药物的合并提高了疗效，因为它以特有的协同或相加方式靶向关键途径。这种方法可能降低耐药性，同时提供治疗性抗癌益处，例如降低肿瘤生长和转移潜力，阻止有丝分裂活性细胞，减少癌症干细胞群，并诱导细胞凋亡。大多数转移性癌症的5年生存率仍然很低，开发新的抗癌药物的过程成本高昂且非常耗时。因此，目前正在考虑针对生存途径的新战略，以负担得起的费用提供高效和有效的结果。一种这样的方法包括重新利用最初用于治疗癌症以外的不同疾病的治疗剂。这种方法主要在FDA批准的药物靶向癌症中发现的类似途径时有效。由于联合治疗中使用的药物之一已经获得FDA批准，因此联合治疗研究的总体成本降低。这提高了治疗的成本效益，从而使“医疗服务不足者”受益。此外，一种将重新利用的药物与其他治疗方法相结合的方法在减轻肿瘤负担方面显示出有希望的结果。在这篇系统性综述中，我们讨论了癌症治疗中常见的重要途径。此外，我们还回顾了自2012年以来在临床试验和研究中受到欢迎的重要的再利用或主要抗癌药物。
Combination therapy, a treatment modality that combines two or more therapeutic agents, is a cornerstone of cancer therapy. The amalgamation of anti-cancer drugs enhances efficacy compared to the mono-therapy approach because it targets key pathways in a characteristically synergistic or an additive manner. This approach potentially reduces drug resistance, while simultaneously providing therapeutic anti-cancer benefits, such as reducing tumour growth and metastatic potential, arresting mitotically active cells, reducing cancer stem cell populations, and inducing apoptosis. The 5-year survival rates for most metastatic cancers are still quite low, and the process of developing a new anti-cancer drug is costly and extremely time-consuming. Therefore, new strategies that target the survival pathways that provide efficient and effective results at an affordable cost are being considered. One such approach incorporates repurposing therapeutic agents initially used for the treatment of different diseases other than cancer. This approach is effective primarily when the FDA-approved agent targets similar pathways found in cancer. Because one of the drugs used in combination therapy is already FDA-approved, overall costs of combination therapy research are reduced. This increases cost efficiency of therapy, thereby benefiting the “medically underserved”. In addition, an approach that combines repurposed pharmaceutical agents with other therapeutics has shown promising results in mitigating tumour burden. In this systematic review, we discuss important pathways commonly targeted in cancer therapy. Furthermore, we also review important repurposed or primary anti-cancer agents that have gained popularity in clinical trials and research since 2012.
登录
查看更多内容
影响因子：
17.3
作者：
Blagosklonny, MV
通讯作者：
Blagosklonny, MV
影响因子：
3.7
作者：
Carlin S;Khan N;Ku T;Longo VA;Larson SM;Smith-Jones PM
通讯作者：
Smith-Jones PM
影响因子：
45.3
作者：
Albain, Kathy S.;Nag, Shona M.;O'Shaughnessy, Joyce
通讯作者：
O'Shaughnessy, Joyce
DOI：
10.1007/978-94-007-7359-2_11
发表时间：
2014-01-01
期刊：
CARBONIC ANHYDRASE: MECHANISM, REGULATION, LINKS TO DISEASE, AND INDUSTRIAL APPLICATIONS
影响因子：
--
作者：
Benej, Martin;Pastorekova, Silvia;Pastorek, Jaromir
通讯作者：
Pastorek, Jaromir
影响因子：
5.8
作者：
Bryan, Holly K.;Olayanju, Adedamola;Park, B. Kevin
通讯作者：
Park, B. Kevin